microdosing a glp-1 Why Microdosing? Closer Look at Reported Benefits Curious about GLP-1 microdosing and

In various healthcare settings, acute kidney disease (AKD) has seen a rising incidence 4,5 , with associated heightened risks of all-cause mortality, end-stage kidney disease, and chronic kidney disease (CKD) 6

Your first shot will be at a dosage of 0.25 mg

A simple daily rhythm for GLP-1 weeks 512 Use this as a flexible framework rather than a strict plan

The International Classification of Diseases (ICD) 9 and ICD10 codes used to define T2D are listed in Supplemental Table 1

Gastric Emptying Modulation GLP2 transiently delays gastric emptying, similar to selective GLP-1 receptor agonists: Slowed rate of nutrient absorption from the gastrointestinal tract Reduced postprandial glucose excursions Effect is most pronounced after initial doses and diminishes with continued treatment Contributes to improved glycemic control through multiple complementary mechanisms Central Nervous System Effects Appetite Regulation Both GIP and GLP-1 receptors are expressed in brain regions controlling appetite and food intake: Reduced food intake and appetite through central nervous system receptor activation Promotion of satiety signals leading to decreased caloric consumption Potential modulation of reward-related feeding behaviors Weight loss effects that appear mediated through both homeostatic and hedonic feeding pathways Clinical trials have demonstrated substantial weight reduction, with participants experiencing decreased appetite as a commonly reported effect of GLP2 treatment

A1c is 7.2%